Julie Clark
Chief Tech/Sci/R&D Officer chez OPTHEA LIMITED
Profil
Julie Clark is a professional with experience in the pharmaceutical and biotechnology industries.
She is currently the Senior Vice President of Clinical Development at Opthea Ltd.
and Vice President of Clinical Development at IVERIC bio, Inc. Her former positions include Associate Director of Medical Affairs at Regeneron Pharmaceuticals, Medical Director of Retina at Novartis Corp., Medical Director at Thrombogenics, and Chief Medical Officer at Adverum Biotechnologies.
Dr. Clark received her undergraduate and doctorate degrees from Wake Forest School of Medicine and her undergraduate degree from Wake Forest University.
She also received a graduate degree from The Johns Hopkins University.
Postes actifs de Julie Clark
| Sociétés | Poste | Début |
|---|---|---|
| OPTHEA LIMITED | Chief Tech/Sci/R&D Officer | 01/02/2024 |
| IVERIC BIO, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Julie Clark
| Sociétés | Poste | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 22/10/2021 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/10/2012 |
Thrombogenics, Inc.
 Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Chief Tech/Sci/R&D Officer | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Julie Clark
| Wake Forest School of Medicine | Doctorate Degree |
| Wake Forest University | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| OPTHEA LIMITED | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Thrombogenics, Inc.
Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Commercial Services |
